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Y-box binding protein YB-1 is a multifunctional protein involved in cell proliferation, regulation of transcription and translation.
Our previous study indicated that disruption of one allele of Chk-YB-1b gene in DT-40 cells resulted in major defects in the cell
cycle. The abnormalities seen in heterozygous mutants could be attributed to a dominant negative eﬀect exerted by the disrupted
YB-1 allele product. To test this hypothesis the N-terminal sequence of the YB-1 was fused with the third helix of antennapedia
and the green ﬂuorescent protein. These puriﬁed fusion proteins were introduced into rat hepatoma cells and their eﬀect on cell
proliferationwasstudied.ResultsindicatethattheN-terminal77aminoaciddomainoftheYB-1proteininducedthecellstoarrest
in G2/M phase of the cell cycle and undergo apoptosis. Additional deletion analysis indicated that as few as 26 amino acids of the
N-terminus of YB-1 can cause these phenotypic changes. We further demonstrated that this N-terminal 77 amino acid domain of
YB-1 sequesters cyclin D1 in the cytoplasm of cells at G2/M phase of cell cycle. We conclude that the N-terminal domain of YB-1
plays a major role in cell cycle progression through G2/M phase of cell cycle.
Copyright © 2009 Payal Khandelwal et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Y-box binding proteins are members of the Cold Shock
Domain (CSD) super family of proteins [1]. They are
involvedintheregulationoftranscription[2,3],modulation
of translation [4], DNA repair [5], and drug resistance [6–
8], stress response to extracellular signals [9, 10] and in an
early stage of embryogenesis [11, 12]. Several studies also
showed up-regulation of YB-1 protein levels in proliferating
cells in comparison to quiescent or non-proliferating cells
[1, 13]. YB-1 activates many genes implicated in cell
proliferationincludingDNApolymeraseα[14],proliferating
cell nuclear antigen (PCNA) [15, 16], thymidine kinase and
topoisomeraseII[15,17].However,themechanismbywhich
YB-1 promotes cell proliferation is not understood.
Knock-outstudieshavebeendonetogaininsightintothe
function of YB-1 in cell proliferation. We showed previously
that targeted disruption at the 5  end of one allele of chicken
YB-1 gene in DT-40 cells resulted in major cell cycle defects,
including a slower doubling time, increased genomic DNA
content, increased cell size and apoptosis in a fraction of the
cell population [18]. In contrast, another group found that
YB-1+/− heterozygous mutants did not show any apparent
growth defects, whereas YB-1−/− cells exhibited a markedly
reduced growth phenotype [19]. Targeted disruption at the
3  end of one allele of YB-1 rendered mouse embryonic stem
cellsmoresensitivetocisplatinandmitomycinCwithoutany
apparent growth defects [20]. Furthermore, down regulation
of YB-1 by shRNA resulted in a signiﬁcant reduction in the
rate of proliferation and increased rate of apoptosis [21].
These studies indicated that the amino terminus of YB-
1 may be involved in cell proliferation. A deﬁnitive role
for YB-1 in cell proliferation has been demonstrated by
knocking out both alleles of YB-1 in mice [12]. These mice
are embryonic lethal, indicating a non-redundant role for
YB-1 in early embryonic development. Further studies with
YB1−/− ﬁbroblasts showed greatly reduced cell proliferation
and altered cell morphology, demonstrating a critical role for
YB-1 in cell proliferation [12].
In our earlier studies [18] we speculated that the altered
phenotypes we observed in DT-40 cells might be due to
a dominant negative eﬀect exerted by a putative truncated2 International Journal of Cell Biology
protein encoded by the disrupted YB-1 allele. If this assump-
tion is correct, then introduction of the N-terminal domain
of YB-1 into cells should mimic the phenotypic changes
observed in the mutant DT40 cells [18]. Therefore, we
constructed clones expressing either the 26 or 77 amino acid
polypeptide sequence corresponding to the N-terminus of
YB-1. We also made an internal deletion which removed
the alanine and proline-rich sequence of the N-terminal 77
amino acids of YB-1. These polypeptides were fused with
the antennapedia homeodomain, which facilitates receptor
independent uptake of the proteins into cells and a reporter
green ﬂuorescent protein (GFP) to monitor the uptake and
cellular localization of the proteins. These fusion proteins
were introduced into rat hepatoma cells and their eﬀect
on cell growth studied. Our results clearly indicated a role
for YB-1 in cell proliferation which is mediated by the N-
terminal domain of YB-1 probably by sequestering cyclin D1
in the cytoplasm, thus blocking cell cycle progression from
G2/M.
2.MaterialsandMethods
Antibodies and Reagents. All the chemical reagents, unless
otherwise speciﬁed were from Sigma-Aldrich (St. Louis,
MO). Cell culture media were from Invitrogen-GIBCO
(Carlsbad,CA).TheYB-1polyclonalantibodywasgenerated
for our lab by Sigma. Primary antibodies and ﬂuorescent-
labeledsecondaryantibodieswereobtainedfromInvitrogen-
Molecular probes (Carlsbad, CA).
CloningandExpressionofAPGFP-FusionProteins. ThepUC9
vectorwasmodiﬁedinourlabandthethreesequencesofYB-
1 were cloned in frame with an upstream sequence coding
forthe16aminoacidlongantennapediahomeodomain(AP)
and downstream sequence coding for GFP(Figure 2(a)). The
three clones APYB77GFP, APYB36GFP, APYB26GFP and the
control clone APGFP, which lacked the YB-1 sequence, were
transformed into E. coli BL21DE3 cells. Log phase cultures
were induced overnight with 1mM IPTG and proteins were
puriﬁed.
Puriﬁcation of Proteins. Inclusion bodies were isolated and
solubilized as described [22] and the fusion proteins were
further puriﬁed from the supernatants using DEAE Sephacel
ion-exchange chromatography at 4◦Ca sd e s c r i b e d[ 23]. The
expected fusion proteins were detected in fractions eluted
with 0.3M NaCl. These fractions were dialyzed overnight
with 4 changes of TNG buﬀer (50mM Tris-HCl, pH 8.0,
100mM NaCl and 5% glycerol). Purity of the proteins was
determined by running triplicates of the protein fractions on
a15%SDS-PAGEgelfollowedbycoomassiestainingorsilver
staining and western blotting with GFP antibody. Protein
concentration was determined using BCA protein assay kit
(Pierce- Rockford, IL).
Synchronization and Treatment of Cells. Rat Hepatoma cells
(ATCC-H-411E)weregrowninMinimumEssentialMedium
supplemented with 10% FBS, 100U/mL Penicillin and
100μg/mL Streptomycin, in a humidiﬁed incubator main-
tained at 37◦C and 5% CO2. Cells fed every day were sub-
cultured 1:5 on conﬂuency, using 0.05% trypsin-EDTA. For
experimental analysis, cells were incubated with 40μg/mL of
the puriﬁed proteins for the indicated time periods. Double
thymidine block was used for synchronization of cells in G1
asdescribed[24].ForG2/Mphasesynchronizationcellswere
i n c u b a t e dw i t h1t o2 . 5μg/mL nocodazole for 14 to 24hrs.
Immunoblotting. Cells were washed and lysed with RIPA
buﬀer following the published protocol [25]. For nuclear
and cytoplasmic fractions, the cells were scraped in 100μL
ice cold PBS and centrifuged at 500g for 5min. The cell
pellet was resuspended in 100μLB u ﬀer A (50mM NaCl,
10mM HEPES pH-8.0, 500mM sucrose, 1mM EDTA,
0.2% Triton-X-100, freshly added protease inhibitors and
7mMβ-mercaptoethanol), vortexed at high speed for 45sec
and centrifuged at 2000g for 2min at 4◦C. The resulting
supernatant was used as cytoplasmic extract. The pellet was
resuspended in 100μLB u ﬀer B (Buﬀer A with 25% glycerol
and 0.1mM EDTA) and nuclei were pelleted at 2000g for
2min at 4 ◦C. The pellet was dissolved in 50μLB u ﬀer C
(Buﬀer B with 350mM NaCl), incubated on ice for 30min
with intermittent high speed vortexing and spun down at
11000g for 15min at 4◦C. The supernatant was diluted to
100μL with PBS and used as nuclear extract. Equal amounts
of samples were analyzed on SDS-PAGE gel. 1:7500 dilution
of Antirabbit GFP antibody was used as primary antibody
for overnight incubation at 4◦C. 1:15000 dilution of HRP-
conjugated Antirabbit IgG was used as secondary antibody
for 2hr at room temperature. The blot was developed using
chemiluminescence kit (Pierce, Rockford, IL) according to
the manufacturer’s protocol.
Immunoprecipitation. Equal amounts of whole cell lysates
or nuclear and cytoplasmic extracts were diluted to 500μL
with lysis buﬀer and incubated with 1:2000 dilution of
cyclin A, B1, D1 D2 and GFP antibodies overnight at 4◦C.
Equal amount of Protein A Sepharose beads (Amersham
Biosciences—Piscataway, NJ) was added to each sample and
incubated for 2hr at room temperature. The beads were
pelleted down at 8000g for 4min and the pellet was washed
with lysis buﬀer twice. The resulting pellet was resuspended
in sample buﬀer and loaded onto SDS-PAGE gels.
Immunocytochemistry and Indirect Immunoﬂuorescence.
CellswererinsedtwicewithPhosphatebuﬀeredsaline(PBS),
ﬁxed for 15min. with 4% p-formaldehyde, washed twice
with PBS and stored at 4◦C. Cells were blocked with 5% goat
serum and 3% BSA in PBS for 30min. and rinsed with PBS
thrice.Thenthecellswereincubatedwithprimaryantibodies
Antirabbit GFP (1:500) or Antirabbit YB-1 (1:300) and
Antimouse cyclin D1 (1:300) for 3hrs followed by several
washes with PBS. Subsequently cells were incubated with
secondary antibodies FITC conjugated Antirabbit IgG
(1:500) and Texas-Red conjugated Antimouse IgG (1:500)
for 1hr at room temperature in dark room. Coverslips
were washed several times with PBS and once with water toInternational Journal of Cell Biology 3
remove any salts and left to air-dry for 45min in absence of
light. The coverslips were mounted onto glass slides using
Vectashield Mounting Medium containing DAPI (Vector
Laboratories—Burlingame, CA) to counterstain nuclei. The
slides were stored at −20◦C until analyzed by microscopy.
Confocal Microscopy. Confocal images were captured on
LSM 510 laser-scanning three-color microscope (Carl Zeiss,
Jena, Germany) using Argon laser at 75% output and HeNe1
laser at excitation wavelengths 488nm and 543nm, respec-
tively.Opticalslicethicknesswassetto0.3μm,magniﬁcation
to 40× and sections presented were taken approximately
at the mid height level of cells. Photomultiplier gain and
laserpowerwereidenticalwithineachexperiment.Apoptotic
blebs were seen using Axioplan 2 epiﬂorescent microscope
(Zeiss, Germany). DAPI ﬂuorescence was captured using
the 63× magniﬁcation lens of the microscope. Axiovision
software was used to capture zvi-stacks of images. Expo-
sure was set using control nuclei and was ﬁxed for each
experiment. A minimum of 100 stained cells were scored for
each experiment. All images were analyzed and adjusted for
contrast in Adobe Photoshop 5.0 (San Jose, CA).
DNA Fragmentation. Exponentially growing cells were incu-
bated with the fusion proteins for 24, 48 and 72hr. Analysis
of DNA fragmentation was done as described [18].
FACS Analysis. Cells were harvested by trypsinization or
scraping on ice and pelleted at 500g for 5min. They were
washed with PBS, ﬁxed with ice cold 70% EtOH, incubated
on ice for 45min and centrifuged at 500g for 5min. The
pelletwaswashedwithHanksBalancedSaltSolution(HBSS)
containing 1% BSA, resuspended in propidium iodide buﬀer
(1:1dilution of20ug/mLofPI inHBSSand1mg/ml RNAse
A) and incubated for 30min in a 37◦C water bath. Samples
were analyzed using a Becton Dickinson FACS Calibur. For
analysis of apoptotic cells, Aposcreen Annexin V-FITC kit
(Southern Biotechnology Associates Inc., Birmingham, AL)
was used according to the manufacturer’s protocol. Cell
debris was excluded from the FACS analysis by appropriate
forward and light scatter gating. Cell cycle proﬁles were
analyzed and bar graphs were plotted using Microsoft
Excel.
3. Results
3.1. APYBGFP and APGFP Fusion Proteins Are Internalized
and Stable Inside Cells. Earlier we disrupted one allele of the
YB-1 gene in DT-40 cells and observed profound cell cycle
defects [18]. We proposed that this eﬀect could be due to
truncated proline-rich polypeptide encoded within exon 1
andproducedbythedisruptedallele.Inordertotestwhether
the putative truncated protein could be responsible for the
previously observed results, we developed an expression
cassette containing the amino-terminal 77 amino acids of
YB-1 inserted between the 16 amino acid antennapedia
peptide and a GFP reporter. The amino acid sequence of
these clones is shown in Figure 1(a). This construct will
be referred as APYB77GFP (Figure 1(a) Line drawing). Two
other fusions containing the 26 N-terminal amino acids of
YB-1 (APYB26GFP) and a clone with an internal deletion
that removed the alanine-proline-rich sequence from the N-
terminal 77 amino acids of YB-1 (APYB36GFP) were also
generated(Figure 1(b)Linedrawings).Thesefusionproteins
were puriﬁed to more than 80% homogeneity as assessed
by polyacrylamide gel electrophoresis and their sizes were
conﬁrmed by western blotting (Figure 1(b)).
In order to show that the antennapedia peptide can
direct the cellular uptake of the YB-1 fusion proteins,
we incubated rat hepatoma cells with 40μg/mL of each
protein for 3 and 18hrs. Cellular extracts were prepared
and analyzed by western blotting using anti-GFP antibody.
Results presented in Figure 2 indicate that that the fusion
proteins are internalized as early as 3hrs (Figure 2(a), lanes
marked L) and continued to accumulate for at least 18hr
(Figure 2). At this time more than 80% of cells have taken
up the fusion proteins indicating that the antennapedia
peptide allows the cells to take up the proteins eﬃciently (see
Figure 3) Similar results were obtained with primary cells
isolated from rat aortic smooth muscle (RASM) (data not
shown). These results indicate that the fusion proteins are
readily internalized by tumor and primary cells.
3.2. N-Terminal Domain of YB-1 Is Responsible for Cyto-
plasmic Localization. Having demonstrated internalization
of all the proteins, we then studied the localization of
these proteins within cells. Cells were incubated with the
fusion proteins for 3 or 18hr and prepared for confocal
microscopy. Results indicated that more than 80% of the
cells had taken up the proteins by 18hrs. APGFP, which did
not contain any YB-1 sequences, was distributed throughout
the cell, that is, in both nucleus and cytoplasm (Figure 3(a)
panels A and E). This is probably due to the fact that
GFP alone can distribute all over the cell unless speciﬁc
targeting signals are included (reviewed in [26]) or that the
cell penetrating antennapedia moiety may be responsible
for the translocation of GFP through both cytoplasmic and
nuclear membranes. In contrast, incubation of the three YB-
1 fusion proteins indicated that both at 3 and 18 hours,
most of the protein was localized only in the cytoplasm
(Figure 3(a),p a n e l sBa n dD ,Ca n dE ,a n dFa n dH ) .T h e s e
resultssuggestthattheaminoterminusofYB-1restrictedthe
fusion proteins to the cytoplasm of cells.
This was further conﬁrmed by immunoblotting analysis.
Nuclear and cytoplasmic extracts of rat hepatoma cells
were analyzed by immunoblotting analysis using anti-GFP
antibodies.ThesestudiesindicatedthattheAPYBGFPfusion
proteins were detected only in the cytoplasmic extracts of
cells even after 18hr, whereas the APGFP was detected both
in nuclear and cytoplasmic extracts (Figure 3(b)). Less than
2 to 3% of the internalized APYBGFP proteins was found in
the nuclei where as in the control APGFP as much as 30 to
40% was detected in the nuclei by 18 hours. We conclude
that the presence of N-terminal amino acid sequence of YB-
1 in the fusion protein is responsible for their restricted
localization to the cytoplasm of cells.4 International Journal of Cell Biology
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Figure 1: Schematic representation of the fusion constructs and the amino acid sequence of truncated YB-1 proteins. (a) Amino acid
sequence of the N-terminal region of each of the truncated YB-1 protein. Note an internal deletion in APYB36GFP which removes the
alanine-proline sequence (b) Line drawing of each fusion containing antennapedia, YB-1 and GFP and size of E. coli expressed fusion
proteins as analyzed by PAGE followed by western blot analysis.
3.3. Cells Incubated with APYBGFP Proteins Arrest at the
G2/M Phase of the Cell Cycle. Having demonstrated the
delivery of the amino-terminal YB-1 peptides into cells, we
wondered whether these YB-1 peptides induce cell cycle
defects similar to those we previously observed in YB-1-
disrupted heterozygous mutant DT-40 cells [18]. Cells were
incubated with each one of these fusion proteins for 24, 48
and 72hrs. Half of the cells were stained with propidium
iodide and subjected to FACS analysis to determine the DNA
content.Ourresultsindicatethat ∼32%ofcellswerearrested
in G2/M phase of the cell cycle following 72 hr incubation
with APYB77GFP (Figure 4) while APYB26GFP induced
more than 24% of the cells to accumulate in G2/M following
the same 72hr incubation (Figure 4). In contrast, only about
10% APYB36GFP-incubated cells were in G2/M (Figure 5),
whichisverysimilartotheAPGFP-incubatedcellswhereless
than 6%–8% of the cells were in the G2/M phase (Figure 4).
These results suggest that the N-terminal sequence of YB-1,
containingthealanine-proline-richdomain,maybeinvolved
in regulating the progression of cells from G2/M to G1.
In order to show that the block in G2/M phase was
not due to diﬀerences in the uptake of the fusion proteins,
the remaining half of the samples was used to quantify the
mean GFP ﬂuorescence in the GFP positive cells. The results
presented in Figure 4(b) indicated that the percentage of
GFP-positive cells was similar for all the fusions. In addition,
no diﬀerence was observed in the mean GFP ﬂuorescence
of diﬀerent fusion proteins. These results suggest that the
cell cycle arrest in APYBGFP-incubated cells is not due
to variation in the number of fusion protein-positive cells
or amount of the internalized proteins, but is due to the
presence of YB-1 N-terminal sequence. Further, this data
clearly implicate the N-terminus of YB-1 in the arrest of cells
at the G2/M phase of the cell cycle.International Journal of Cell Biology 5
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Figure 2: Evidence that APYBGFP and APGFP fusion proteins get
internalized into cells. Whole cell extracts of rat hepatoma cells
incubated with each fusion protein for 3 and 18hr were analyzed by
western blotting using anti-GFP antibody. Details of the amounts
used are discussed in Section 2.
3.4. The Amino Terminus of YB-1 Is Involved in Regulating
Apoptosis. Earlier we demonstrated apoptosis in heterozy-
gous mutant DT-40 cells and speculated that this might
be due to a dominant negative eﬀect of the potential
truncated protein encoded by the defective allele [18].
Subsequently another group reported that down-regulation
of YB-1 resulted in an increased rate of apoptotic cell
death, demonstrating a direct relationship between YB-1
levels and apoptosis [20]. Based on these observations we
hypothesized that the N-terminus of YB-1 is involved in
regulating apoptotis.
To test the possibility that the N-terminus of YB-1
regulates apoptosis, we carried out experiments that detect
the presence of phosphatidylserine on the cell surface using
ﬂuorescein-conjugated annexin V and DNA fragmentation,
both of which are hallmarks of apoptosis. Cells were incu-
batedwiththefusionproteinsfor24,48and72hrandhalfof
the cells were stained with annexin V and analyzed by FACS.
Our results indicated that in APGFP-incubated cells less
than 1 to 2% of cells were apoptotic after 72hr incubation
(Figure 5(a)). In contrast, incubation with APYB77GFP
stimulated 22-23% of cells to become annexin V-positive
by 72hrs. Similar results were obtained with APYB26GFP-
incubatedcells(Figure 5(a)).Bycontrast,APYB36GFPisless
eﬀective in causing the cells to undergo apoptosis. Again,
the uptake of these proteins was comparable as evidenced
by the number of GFP positive cells and their mean GFP
ﬂuorescence (Figure 5(c)). These results clearly suggest that
the N-terminal alanine-proline-rich 26 amino acids is part
of a major death domain of YB-1.
These results were further substantiated by DNA frag-
mentation analysis. DNA from cells incubated with the
fusion proteins for various time periods was analyzed by
agarose gel electrophoresis. It can be seen that the pattern of
DNA fragmentation, as evidenced by the appearance of the
180–200bp ladder, was clearly seen with the DNA from cells
treated with YB-1 containing fusion proteins (Figure 5(b))
but not with cells incubated with the control fusion protein,
APGFP. Futher, staining of the nuclei with DAPI indicated
chromatin condensation and broken nuclei in cells treated
with the APYBGFP proteins for 72 hr but not in APGFP-
incubated cell nuclei which showed normal appearance(see
in Supplementary Material Figure S1 available online at doi:
10.155/2009/243532). Based on these results we conclude
that the amino terminal region of YB-1 is involved in
apoptosis.
3.5.InteractionoftheN-TerminalDomainofYB-1withCyclin
D1. It has been shown that YB-1 regulates transcription of
G2/M phase cyclins A and B1 [27]. Since cyclin D1 is upreg-
ulated during G2 phase of cell cycle by Ras-mediated transla-
tional control of its mRNA, and since it is localization within
the nucleus is very important for cell cycle progression, we
wonderedwhetherYB-1interactswithanyofthesecellcycle-
speciﬁc cyclins. In order to study this interaction, whole cell
extracts of rat hepatoma cells were immunoprecipitated with
antibodies for cyclins A, B1, D1 and D2 and examined for
the presence of YB-1. Our results clearly indicate that YB-1
predominantly interacts with cyclin D1 as this is the major
band observed in the pull-down assays (Figure 6(a)). We
observed a minor band with cyclins B and D2 which are also
upregulated in G2. In order to show that this interaction is
not due to an artifact of protein extraction methods used,
we carried out immunoprecipitations of extracts isolated
from asynchronous as well as from nocodazole-treated
cultures. Nocodazole, as expected, blocked cells in the G2/M
(Supplementary Figure S2). Since anticyclin D1 antibody
pulled-down YB-1 from nocodazole-treated cell extracts,
it indicates that YB-1 interacts with cyclin D1. Reciprocal
experiments using anti-YB-1 antibody conﬁrmed that YB-1
indeed binds to cyclin D1 (Supplementary Figure S3).
In order to investigate if YB-1 and cyclin D1 co-localize
in cells in diﬀerent phases of the cell cycle, we analyzed
their distribution in G1/S and G2/M phase synchronized
cells using confocal microscopy. We observed that in the
asynchronized and G1/S phase synchronized cells YB-1 was
predominantly cytoplasmic (Figure 6(b), Panels A and D)
whereas Cyclin D1 was predominantly nuclear (Figure 6(b),
Panels C and F) with minimal co-localization (Figure 6(b),
Panels B and E). However, in the G2/M phase-blocked cells
YB-1 and cyclin D1 were partially co-localized mainly in the
cytoplasm (Figure 6(b),P a n e l sG ,Ha n dI ) .
In order to show that this colocalization is due to speciﬁc
interaction between YB-1 and cyclin D1, we carried out
immunoprecipitationswithisolatednuclearandcytoplasmic
extracts using speciﬁc antisera (Supplementary Figures S3A
and S3B). Anticyclin D1 antibody pulled down only cyclin
D1 and anti-YB-1 antibody brought down only YB-1 from
the cytoplasm indicating that these proteins are indeed local-
ized in the nuclei and cytoplasm, respectively, of untreated
cells. However, in the nocodazole-treated cells, which are
arrested in G2 phase, cyclin D1 antibody pulled down YB-
1 from cytoplasm and vice versa. As expected, nocodazole6 International Journal of Cell Biology
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Figure 3: Fusion proteins containing N-terminal YB-1 sequences are restricted to cytoplasm of the cells. (a) Subcellular localization of the
internalized proteins in cells incubated with APYB26GFP (panels B and F), APYB36GFP (Panels C and G), and APYB77GFP (Panels D and
H) or APGFP control (A and E) are shown. Representative cells are marked by arrows. In order to show in more detail a representative
ﬁeld (marked by a dashed square) from the 18 hour panels was magniﬁed and shown in a separate box on the right of the ﬁgure. (b)
Immunoblot analysis of nuclear and cytoplasmic extracts using polyclonal GFP antibody. Note that the three APYBGFP proteins are seen
only in cytoplasmic extracts at both time points whereas APGFP was detected in both nuclear and cytoplasmic extracts.
blocked a large proportion of cells in G2/M phase of cell
cycle(SupplementaryFigure S2).Weconclude thatYB-1and
cyclin D1 interact with each other in the cytoplasm of G2
phase cells. Interestingly when Wortmannin, an inhibitor of
PI-3 kinase and Akt pathway was used, a signiﬁcant amount
of cyclin D1 could be detected in the nuclei (Supplementary
Figure S4). This indicates that the interaction between YB-1
and cyclin D1 depends on phosphorylation of one or both
proteins. Further experiments are necessary to identify the
phosporylation sites.International Journal of Cell Biology 7
0
5
10
15
20
25
30
35
40
A
P
G
F
P
A
P
Y
B
2
6
G
F
P
A
P
Y
B
3
6
G
F
P
A
P
Y
B
7
7
G
F
P
C
e
l
l
s
i
n
G
2
/
M
p
h
a
s
e
o
f
c
e
l
l
c
y
c
l
e
(
%
)
Cell cycle analysis by propidium iodide staining
A
P
G
F
P 1
A
P
Y
B
2
6
G
F
P
A
P
Y
B
3
6
G
F
P
A
P
Y
B
7
7
G
F
P
A
P
G
F
P
A
P
Y
B
2
6
G
F
P
A
P
Y
B
3
6
G
F
P
A
P
Y
B
7
7
G
F
P
24hrs 48hrs 72hrs
(a)
% of GFP Positive cells—Cell Cycle Analysis.
APGFP APYB26GFP APYB36GFP APYB77GFP
24Hrs. 67 69.6 69.9 70.9
48Hrs. 77.8 82.1 77.8 79.6
72Hrs. 85.8 86.4 84.5 86.5
(b)
Figure 4: Internalization of YB-1 fusion proteins results in cell
cycle arrest at the G2/M phase. Rat hepatoma cells incubated with
each of the fusion proteins were stained with propidium iodide
and subjected to FACS analysis (a). Three independent experiments
were performed for statistical analysis and all the values (per
cent of cells) reported are absolute to P<. 001. Panel B shows
the percentage of cells that have taken up the fusion protein
as quantiﬁed by FACS analysis. This indicates that there is no
diﬀerence in the extent of protein uptake by cells incubated with
the fusion proteins.
3.6. Interaction of the YB-1 N-Terminal Domain with Cyclin
D1 in G2/M Phase Blocked Cells. In order to determine
if the amino terminus of YB-1 interacts with cyclin D1,
whole cell extracts of asynchronized and cells synchro-
nized in G2/M phase using nocodozole were incubated
with GFP antibody and probed for cyclin D1. Anti-YB-
1 immunoprecipitated Cyclin D1 was used as a positive
control. Immunoprecipitation of APGFP incubated cells
acted as a negative control. Cyclin D1 immunoprecipitation
was not observed in asynchronized cells (Figure 6(c)). How-
ever, in nocodazole-blocked cells, cyclin D1 co-precipitated
with both APYB26GFP and APYB77GFP at the 3hr and
18hr time points (Figure 6(c)), while it was absent in the
immunoprecipitates prepared from APYB36GFP-incubated
cells. Since asynchronous cultures also contain some cells
in G2/M we expect some interaction between cyclin D1
and YB-1, as shown in supplementary Figure S3B. We have
not observed such an interaction with the fusion proteins
in aynchronous cells. This may be due to sensitivity of
the technique or that the interaction in the presence of
endogenous YB-1 may be masking detection. Nevertheless,
theseresultssuggestthatthealanine-proline-richN-terminal
sequence of YB-1 may be involved in sequestering cyclin D1
in the cytoplasm when the cells are blocked in the G2/M
phase of cell cycle. Retention of cyclin D1 in the cytoplasm
of G2/M phase cells by the YB-1 fusion proteins may be
responsible for the observed eﬀects of these fusions on cell
cycle progression and apoptosis.
4. Discussion
YB-1 expression is closely associated with cell proliferation.
For example, YB-1 is highly expressed in regenerating liver
and liver cancers but barely detectable in normal adult liver
w h e r ec e l l sa r eq u i e s c e n t[ 28, 29]. Our earlier studies showed
that disruption of one allele of Chk-YB-1b gene resulted in
abnormalities in the heterozygous DT-40 mutants, including
slower growth rate and increased genomic DNA content
that is associated with apoptosis [28]. We speculated that
the defects seen may be due to a dominant negative eﬀect
of the putative N-terminal truncated protein encoded by
the disrupted YB-1 allele. If our assumption was correct,
then introduction of peptides corresponding to the amino
terminus of YB-1 should mimic the defects that were
observed in the mutant DT40 cells [18].
The antennapedia peptide was shown to be the most
eﬃcient and least cytotoxic of all cell penetrating peptides
[30].ThereforetheYB-1sequenceswereclonedinsuchaway
that the fusion proteins carried the antennapedia peptide at
the amino end and a reporter GFP sequence at the carboxyl
end. We report here that internalization of the four APGFP
fusion proteins occurs at high eﬃciency in exponentially
growing rat hepatoma cells. The control protein, APGFP,
which does not have any YB-1 sequence, is distributed
throughoutthecell—bothnucleiandcytoplasm.Incontrast,
YB-1 fusion proteins are restricted to the cytoplasm of cells.
SinceAPGFPisdistributedalloverthecell,itappearsthatthe
YB-1 moiety is responsible for the cytoplasmic localization.
The ability of the YB-1 N-terminus to associate with
cyclin D1 and potentially retain it in the cytoplasm of cells
may account for the eﬀect of the YB-1 fusions on cell cycle
progression and apoptsis. Cyclin D1, encoded by the Bcl-
1 gene, is a putative protooncogene, and previous studies
have shown that both YB-1 and cyclin D1 are upregulated
in many neoplasms [1, 31, 32]. Although YB-1 is generally a
cytoplasmic protein and cyclin D1 a nuclear protein, YB-1 is
found in the nucleus in mid G1 to S phase [27] at the same
time as cyclin D1. Cyclin D1 relocates to the cytoplasm at the
end of S phase and into the G2 phase [33, 34], when YB-1 is
also concentrated in the cytoplasm. The levels of cyclin D1 in
the G2/M phase of cell cycle are crucial for the cells to decide
if they have to undergo another round of replication.
It has been shown that cyclin D1-knockout mouse
embryos survive for about 13 days and then die [35].
Cells isolated from these mice grow normally although at
a reduced rate. However, in epithelial cells cyclin D2 com-
pensates for the loss of cyclin D1 indicating the importance
of these cyclins in cell proliferation [36]. Cyclin D1 is
considered to be a G1 cyclin, as its interaction with Cdk4/6
contributes to the phosphorylation of Rb protein and also
sequesters the Cdk inhibitors, which is required for the cell
cycle progression to the S phase [37].8 International Journal of Cell Biology
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Figure 5: Cells incubated with the three APYBGFP proteins show signiﬁcant apoptosis. (a) Rat hepatoma cells incubated with each of the
fusionproteinswerestainedwithFITC-conjugatedannexinVandsubjectedtoFACSanalysis.PanelCshowsthenumberofcells(percentage)
that have taken up the fusion proteins as quantitated by FACS analysis. (b) Agarose gel electrophoresis of DNA isolated from cells incubated
with the fusion. (c) Percentage of cells taken up the fusion protein as quantitated by FACS analysis.
Cyclin D1 levels also increase in G2 and are maintained
throughout mitosis and G1 [10, 34, 38]. The regulation
appears to be at posttranscriptional level, indicating that de
novosynthesisofcyclinD1occursduringG2phase.Itsfateis
determined through receptor-coupled Ras signaling [34, 37].
It is likely that when cyclin D1 is present in cytoplasm in
G2 that the amino end domain of YB-1 sequesters cyclin D1
and prevents its import into nucleus. Nuclear translocation
of YB-1 requires phosphorylation by the serine-threonine
protein kinase Akt at ser-102 in the CSD of YB-1 [39–
41]. This phosphorylation also induces translation of several
cellular mRNAs [42]. Since both the CSD and the carboxy
terminal acidic-basic domains are missing in our fusion
proteins, many of the functions carried out by the full length
endogenous YB-1 molecule are disrupted. As a consequence,
the cellular protein(s) that interact with the N-terminal YB-
1s e q u e n c ea ﬀect downstream signaling leading to cellular
damage, which keeps the cells in G2, giving an opportunity
f o rc e l l st or e c o v e ro ru n d e r g oa p o p t o s i sp r o b a b l yi nap 5 3 -
dependentpathway[24,37].Thedatap r o vid edher esuggests
that the interaction between YB-1 and cyclin D1 play a
critical role in regulating cyclin D1 function at the G2/M
phase of the cell cycle.
Stabilization and nuclear accumulation of cyclin D1
depends on PI3-K, Akt pathway, which can negatively regu-
lateGSK-3β[43],aserine/threonineproteinkinase,regulates
cyclin D1 expression by regulating mRNA transcription and
protein degradation (reviewed in [43]). Phosphorylation of
cyclin D1 as well as YB-1 depends on the PI3-K and Akt
pathway. YB-1, upon phosphorylation is translocated into
nucleus where it directly induces the p110α catalytic subunit
of PI3-kinase [39, 44]. Similarly, cyclin D1 is also regulated
by PI3-kinase, Akt and GSK-3β (reviewed in [32]). Cyclin
D1 in the nucleus is important for cell cycle progression and
export from cytoplasm to nucleus is critical for G2/M esit
[34]. Normally cyclin D1 is exported to the cytoplasm where
it is degraded by the ubiquitin pathway [32].
The fact that Wortmannin, an inhibitor of PI3-kinase-
Akt pathway, stimulates the nuclear localization of cyclin
D1 in nocodazole-treated cells, suggests that the interactionInternational Journal of Cell Biology 9
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Figure 6: Evidence that YB-1 interacts with Cyclin D1. (a) Immunoprecipitation of rat hepatoma cell extracts with anticyclin antibodies
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between cyclin D1 and YB-1 and resulting cytoplasmic
localization of cyclin D1 depends on the phosphorylation
of YB-1 or cyclin D1 or both. YB-1 is known to be
phosphorylated on its ser 102 in CSD by both Akt and the
p90 ribosomal S6 kinase. This phosphorylation allows YB-1
toshuttle into nucleus whereit induces transcriptioin of PI3-
K α110 catalytic subunit [39]. However, in the APYB77GFP
andAPYB26GFP,thisphosphorylationsiteisnotpresentand
as a result this N-terminal domain sequesters the cyclin D1
and prevents its movement to the nucleus. This could cause
the cell cycle to arrest in G2/M.
YB-1 is known to interact with several cellular proteins
including those involved in DNA synthesis, DNA repair,
transcription,andtranslation.ItalsobindstoseveralmRNAs
and represses translation [42]. Depending on the type of cell
and the cell cycle stage these interactions may be required
for nuclear translocation and/or for cytoplasmic retention
of various cellular factors. It is generally known that cells
halted in G2/M are unstable, and during this time the cell
survival depends on several proteins including p53, p21 and
cyclins, which determine the fate of the cells, that is, whether
t og of o ra n o t h e rr o u n do fc e l lc y c l eo ra p o p t o s i s .W h e nf u l l10 International Journal of Cell Biology
length YB-1 binds to appropriate targets and elicit proper
response, the cell cycle progresses normally; however, when
the N-terminal sequence binds to proteins such as p53 [45]
or cyclin D1 and keeps them in a diﬀerent compartment of
the cell, then it cannot elicit the same response and hence the
defects.
It has been shown that cells blocked in the G2/M phase
o fc e l lc y c l ea p p e a rt ob eu n s t a b l ea n du n d e r g oa p o p t o s i s
[33, 34, 46]. In addition, it is known that repair of any
damaged DNA takes place during G2 and YB-1 has been
implicated in this process. In our experiments we found that
the N-termainal region of YB-1 stimulated cells to arrest
in the G2/M phase of the cell cycle. This dominant eﬀect
of the N-terminus of YB-1 may be due to the ability of
YB-1 to regulate centrosome function by binding to actin
[47] and centrosomes during mitosis [48]. Inhibition of
centrosome function can lead to chromosomal instability
and aneuploidy [46, 49], which may lead to a block in cell
cycle and apoptosis. Our data, which are consistent with
these previous observations, suggest a critical role for the
YB-1 N-terminal domain in regulating cell proliferation and
apoptosis.
In summary, in this report we demonstrated co-
localization of YB-1 and Cyclin D1 in the cytoplasm of G2/M
phaseblockedcells.Furthermore,wepresentevidenceforthe
interaction of Cyclin D1 with fusion proteins APYB26GFP
and APYB77GFP in G2/M phase blocked cells. We propose
that YB-1 binds to cyclin D1 and sequesters it in the
cytoplasm.ThiscausesthecellstoarrestinG2/Mphaseofthe
cell cycle and protects cyclin D1 from degradation, which is
important for G2/M exit. As a consequence of this abnormal
arrest in G2/M arrest, the cells become unstable and undergo
apoptosis. Since cyclin D1 immunoprecipitates APYB77GFP
and APYB26GFP, but not APYB36GFP and correlates with
increasedapoptosis,itislikelythattheinteractionwithcyclin
D1 occurs through the alanine and proline-rich sequence
at the N-terminus of YB-1. Further studies are necessary to
elucidate the physiological importance of the YB-1/cyclin D1
interaction and to precisely identify the domains involved in
this interaction.
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